Sales

Five things for pharma marketers to know: Thursday, July 20, 2017

Five things for pharma marketers to know: Thursday, July 20, 2017

By

About 4.4 billion prescriptions filled in the U.S. in 2016; Sanofi and Ablynx reach I-O deal; biotech M&A slows in H1

Five things for pharma marketers to know: Tuesday, July 18, 2017

Five things for pharma marketers to know: Tuesday, July 18, 2017

By

Novartis raises Alcon forecast; UDG acquires Cambridge BioMarketing; Spark Therapeutics receives priority review for Luxturna gene therapy

Five things for pharma marketers to know: Wednesday, July 12, 2017

Five things for pharma marketers to know: Wednesday, July 12, 2017

By

Former sales reps for Insys plead guilty to kickback allegations; digital health funding on the rise; PhRMA launches campaign about drug costs

Five things for pharma marketers to know: Thursday, July 6, 2017

Five things for pharma marketers to know: Thursday, July 6, 2017

By

The FDA suspends three Keytruda studies; drug and device makers gave $8 billion in payments to providers in 2016; Opdivo beat Yervoy in skin-cancer trial

Five things for pharma marketers to know: Thursday, June 15, 2017

Five things for pharma marketers to know: Thursday, June 15, 2017

By

Google invests in European biotechs; hospitals that restrict sales-rep visits more likely to prescribe cheaper generics; AI could help doctors with new research

Five things for pharma marketers to know: Friday, June 9, 2017

Five things for pharma marketers to know: Friday, June 9, 2017

By

The FDA asks Endo to take opioid off the market; Lilly partners with Swiss biotech; House committee advances PDUFA bill — without off-label provision

Why Novartis' Shah-Mehta chose a career in pharma sales

Why Novartis' Shah-Mehta chose a career in pharma sales

By

The executive director of oncology marketing is fascinated by the resilience of the human body.

Five things for pharma marketers to know: Friday, June 2, 2017

Five things for pharma marketers to know: Friday, June 2, 2017

By

Oncologists more likely to prescribe drugs when receiving travel, meal payments; Tesaro reportedly considering a sale; AbbVie has best pharma reputation

Five things for pharma marketers to know: Wednesday, May 24, 2017

Five things for pharma marketers to know: Wednesday, May 24, 2017

By

Keytruda receives first approval based on a genetic feature and not tumor's location; Alexion reps reportedly crossed ethical lines; profits up at insurers

Five things for pharma marketers to know: Tuesday, May 23, 2017

Five things for pharma marketers to know: Tuesday, May 23, 2017

By

Disease awareness ads can boost drug sales; AstraZeneca's experimental asthma drug cuts steroid use; FDA approves Regeneron and Sanofi's RA drug

Five things for pharma marketers to know: Tuesday, May 9, 2017

Five things for pharma marketers to know: Tuesday, May 9, 2017

By

Sanofi ties price increases to growth rate; Regeneron to target 7,000 docs on new eczema drug Dupixent; NIH and biotech execs meet White House officials

Five things for pharma marketers to know: Wednesday, May, 3, 2017

Five things for pharma marketers to know: Wednesday, May, 3, 2017

By

Teaching hospitals that limit detailing prescribe fewer branded drugs; new ad campaign criticizes drug pricing; Ad Age reports healthcare is fastest growing agency discipline

Five things for pharma marketers to know: Tuesday, May 2, 2017

Five things for pharma marketers to know: Tuesday, May 2, 2017

By

Sales of Merck's Keytruda double in the first quarter; the FDA approves AstraZeneca's immunotherapy; Lilly's insulin is under investigation in two states

Five things for pharma marketers to know: Wednesday, April 26, 2017

Five things for pharma marketers to know: Wednesday, April 26, 2017

By

GSK warns Advair generic competition may affect business in 2017; Lilly plans to meet FDA about baricitinib; FDA warns companies selling 'illegal' products

Top 25 autoimmune brands in 2016, based on U.S. sales

Top 25 autoimmune brands in 2016, based on U.S. sales

By

AbbVie's Humira tops the list, according to data compiled by EvaluatePharma.

Some brands thought to shift online ad dollars, creating uncertainty for WebMD

Some brands thought to shift online ad dollars, creating uncertainty for WebMD

By

This and other changes in the market have created demand for new offerings, like mobile-friendly sites, video, and patient communities.

Top 25 respiratory brands, by sales

Top 25 respiratory brands, by sales

While still the top-selling respiratory drug, GSK's Advair is facing growing competition from BI's Spiriva and Roche's Xolair.

On drug pricing, Acorda CEO is optimistic

On drug pricing, Acorda CEO is optimistic

By

Acorda CEO Ron Cohen applauded Marathon's move to pause the commercial activities for its new DMD drug.

Five things for pharma marketers to know: Monday, February 13, 2016

Five things for pharma marketers to know: Monday, February 13, 2016

By

Sanofi to sell five OTC drugs to Ipsen; Teva reports 33% revenue growth in Q4; Regeneron issued subpoena about support of nonprofits

GSK prepares for Advair competition

GSK prepares for Advair competition

By

If generic versions by Mylan, Hikma, and Vectura are approved mid-year, GSK expects sales of Advair to be flat or decline.

Five things for pharma marketers to know: Thursday, February 2, 2017

Five things for pharma marketers to know: Thursday, February 2, 2017

By

Biogen completes hemophilia spinoff; old drug being tested as a prostate cancer treatment; Merck reports Q4 decline in revenue

Top 25 metabolic brands, by sales, 2015-2016

Top 25 metabolic brands, by sales, 2015-2016

Sanofi's Lantus is the top-selling product with its Lantus franchise. Merck's Januvia and Novo Nordisk's Victoza round out the top 3.

Five things for pharma marketers to know: Tuesday, January 17, 2017

Five things for pharma marketers to know: Tuesday, January 17, 2017

By

Biogen to pay $1.25 billion for patents to MS drugs; Supreme Court to hear Novartis case over Zarxio delay; Merck KGaA inks big-data deal

Five things for pharma marketers to know: Friday, November 18, 2016

Five things for pharma marketers to know: Friday, November 18, 2016

By

Chicago requires pharma rep to have licenses, Acorda CEO backs Califf to remain FDA commish, high-prescribing medicare docs are on the rise

Physicians still rely on medical journals but turn to the web when they have only 10 minutes

Physicians still rely on medical journals but turn to the web when they have only 10 minutes

By

Drugmakers can do a better job of organizing dosing information, safety information, and clinical data on their brand websites, a new survey found.

Five things for pharma marketers to know: Thursday, November 3, 2016

Five things for pharma marketers to know: Thursday, November 3, 2016

By

Sprout investors sue Valeant; FDA raises safety concerns for Cempra's experimental pneumonia drug; NHS gets approval to prescribe eribulin to breast cancer patients

Five things for pharma marketers to know: Wednesday, November 2, 2016

Five things for pharma marketers to know: Wednesday, November 2, 2016

By

Valeant to sell stomach-drug business for $10 billion; Pfizer reports growth in third quarter; sales of hep.-C drugs drive revenue down for Gilead Sciences

Five things for pharma marketers to know: Friday, October 28, 2016

Five things for pharma marketers to know: Friday, October 28, 2016

By

Repatha and Praluent launches described by analyst as waste of money; AstraZeneca halts trial for cancer drug; health exchange choices dwindle

Five things for pharma marketers to know: Tuesday, October 25, 2016

Five things for pharma marketers to know: Tuesday, October 25, 2016

By

Novartis' Entresto and Cosentyx miss sales forecasts; faith-based investor group urges pricing transparency; Amgen invests in digital health

Top 25 neurology products, based on 2016 sales forecasts

Top 25 neurology products, based on 2016 sales forecasts

MS drugs top the list, led by Teva's Copaxone, Biogen's Tecfida and Avonex, and Novartis' Gilenya.